ITIH2 and lung cancer: Also, ITIHs expressions were generally found to be reduced in lung cancers, including lung squamous cell carcinoma (LUSC) (for ITIH1-ITHI5) and lung adenocarcinoma (LUAD) (for ITIH2, ITIH3, and ITIH5); breast cancer (BRCA) (for ITIH2-ITIH5); colon adenocarcinoma (COAD) (for ITIH1, ITIH3, and ITIH5); and kidney chromophobe (KICH) (for ITIH2, ITIH4, and ITIH5) (Figure 2).